Bicycle Therapeutics Files 2024 10-K

Ticker: BCYC · Form: 10-K · Filed: Feb 25, 2025 · CIK: 1761612

Sentiment: neutral

Topics: 10-K, pharmaceuticals, financials

TL;DR

Bicycle Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.

AI Summary

Bicycle Therapeutics plc filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is headquartered in Cambridge, UK. Key financial details and operational highlights for the period are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Bicycle Therapeutics' financial health, strategic direction, and risks for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Bicycle Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What was Bicycle Therapeutics' total revenue for the fiscal year ending December 31, 2024?

The provided snippet does not contain specific revenue figures for the fiscal year ending December 31, 2024.

What is the company's primary business segment?

The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.

When was the company incorporated or formed?

The filing does not explicitly state the incorporation date, but it lists former company names and dates of name changes, indicating a history prior to 2019.

What are the company's current liabilities as of December 31, 2024?

The filing indicates 'AccruedLiabilitiesCurrent' as 21,492,099 as of December 31, 2024.

Who are the major shareholders or affiliated entities mentioned?

Baker Brothers Advisors LP is mentioned as a member entity.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 25, 2025 regarding BICYCLE THERAPEUTICS PLC (BCYC).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing